2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 087

A Growing Problem: Factors Associated with Growth Disturbances in Juvenile Localized Scleroderma
Abstract Number: 018

Abnormal Cortical Grey Matter, White Matter and Subcortical Grey Matter Morphometry is Associated with Disease Features and Quality of Life in Patients with Craniofacial Localized Scleroderma
Abstract Number: 096

Acute Care Utilization in New-Onset Childhood Systemic Lupus Erythematosus: Insights from a Pilot Study
Abstract Number: 140

Adalimumab Tapering is Associated with Short-term, but not Long-term, Advantages for Well-controlled Juvenile Idiopathic Arthritis: A Retrospective Cohort Study using the CARRA Registry
Abstract Number: 141

Age and Activity-Dependent Differences in Intraocular Immune Profile of Chronic Autoimmune Uveitis
Abstract Number: 006

Age Matters: Clinical Profile and IVIG Responsiveness in infants with Kawasaki Disease. A multicentric retrospective analysis of 36 patients from North India
Abstract Number: 132

AI-Assisted Body-Region Recognition for Localized Scleroderma: the 1st Step in Automated LoSCAT scoring
Abstract Number: 027

An Examination of Brain-age-related Deviations from Normative Neurodevelopmental Trajectory in Children with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 103

Anifrolumab Use in Youngsters with Rheumatic Conditions: Case Series and a Review of the Evidence Base
Abstract Number: 089

Anti-CD19 CAR-T Cell Therapy for the Treatment of Severe/Refractory Pediatric Autoimmune Diseases: A Single-Center Case Series
Abstract Number: 046

Antibiotic Exposure and New Diagnosis of Juvenile Idiopathic Arthritis: A Nested Case-Control Study in a Large US Population
Abstract Number: 040

Antiphospholipid Antibody-Mediated Disease: Clinical Characteristics and Outcomes of Catastrophic Antiphospholipid Syndrome and Lupus Anticoagulant Hypoprothrombinemia in a Single Center Pediatric Cohort
Abstract Number: 086

APOL1 Focal Segmental Glomerulosclerosis Requiring Renal Transplant, the Burden of Childhood onset Autoimmune and Autoinflammatory Disease
Abstract Number: 028

Are You Positive About this Positive ANA Referral? Outcomes for ANA Based Referrals to Pediatric Rheumatology and Subsequent Disease Development
Abstract Number: 054

Assessing Completion of Healthcare Transition: A Retrospective Review of Provider Acknowledgment Following Pediatric Rheumatology Transfer

1
2
3
…
10
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].